Monitor for any future 13D conversion or increased activism from Morgan Stanley, though the 13G certification indicates passive intent. The accumulation by a major financial institution adds to institutional credibility but does not signal a near-term catalyst.
Price Chart
How similar events traded
Executive Summary
Morgan Stanley filed a Schedule 13G disclosing a 6.5% passive stake in Rigel Pharmaceuticals as of September 30, 2026, held primarily through its subsidiary Morgan Stanley Capital Services LLC (5.6%). This is a new passive disclosure by Morgan Stanley, adding to the existing institutional holder base alongside State Street's 4.7% stake reported three days earlier. The filing carries no activist intent and is consistent with routine portfolio management.
Key Financial Metrics
Key Facts
- Morgan Stanley disclosed a 6.5% beneficial ownership stake in Rigel Pharmaceuticals as of September 30, 2026.
- Morgan Stanley Capital Services LLC, a wholly-owned subsidiary, holds 5.6% (1,040,643 shares) of the total.
- The filing is a new Schedule 13G, not an amendment, and certifies passive intent under Rule 13d-1(b).
- This follows State Street's 4.7% passive stake filed on November 10, 2026, and prior filings by Soleus Capital and Armistice Capital earlier in 2026.
Financial Impact
Morgan Stanley's aggregate stake of 1,212,656 shares represents 6.5% of Rigel's outstanding shares, valued at approximately $54.5M based on the $838M market cap.
Risk Factors
- Morgan Stanley could convert to a 13D if it later seeks to influence management, though no such intent is indicated.
- The passive nature of the filing limits immediate price impact; the stake is modest relative to Rigel's market cap.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000895421-26-000335 |
| Exhibit: EXHIBIT_NO.99.2.txt | 0000895421-26-000335 |
| Document: 0000895421-26-000335-index-headers.html | 0000895421-26-000335 |
| Document: 0000895421-26-000335-index.html | 0000895421-26-000335 |
| Document: 0000895421-26-000335.txt | 0000895421-26-000335 |
Track record
12 reports on RIGL
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 3/10 Viewing Entry $44.21 Now $43.73 −1.09% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
- Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
- Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
- Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
- May 20, 202625w ago 8-K Neutral 2/10 Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
- May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
- May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers